MedTrace Logo

Early Antibiotic Therapy and Vaccinations in Preterm Infants

NCT05563753 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 82

Last updated 2022-10-12

No results posted yet for this study

Summary

Since the neonatal sepsis is still one of the most common causes of death in preterm infants up to 80% receive an perinatal antibiotic treatment. It is also known that an antibiotic treatment is one of the most important influences for the establishment of the intestinal microbiome. This again is important for the development of an healthy neonatal immunosystem. A pilot study showed that an antibiotic therapy in the first week of life had a negative influence on the vaccine titers of preterm infants.

In this study it will be further investigated if an early antibiotic treatment influences the development of the adaptive immunosystem in preterm infants and if this antibiotic treatment effects the development of the intestinal microbiome.

Conditions

  • Vaccination Reaction

Interventions

DRUG

ABT

any antibiotic therapy in the first week of life

Sponsors & Collaborators

  • University Hospital Tuebingen

    lead OTHER

Eligibility

Min Age
24 Weeks
Max Age
32 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05563753 on ClinicalTrials.gov